Fig. 6From: Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancerProteomic profile of HER2-positive gastric cell lines. Protein expression was examined in SNU-16 (□), NCI-N87 (○), ESO26 (Δ), and OE19 (♦) cell lines after treatment with copanlisib, refametinib, lapatinib, trastuzumab and their combinationsBack to article page